New CAR-T therapy targets Hard-to-Treat myeloma in early trial
NCT ID NCT07185490
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 32 times
Summary
This early-phase study tests a new treatment called IASO104 for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main goal is to check safety and find the right dose in 40 adults aged 18-75.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.